Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: A randomized clinical trial

Diabetes, Obesity and Metabolism

Volumn 16, Issue 4, 2014, Pages 334-343

  Denison, H ^a   Nilsson, C ^a   Lofgren L ^a   Himmelmann, A ^a,b   Martensson G ^a,b   Knutsson, M ^a   Al Shurbaji, A ^a,c   Tornqvist, H ^a   Eriksson, J W ^a,d  

^a ASTRAZENECA R AND D   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

Author keywords

Diacylglycerol o acyltransferase; Diarrhoea; Gastrointestinal hormones; Lipid metabolism; Triglycerides

Indexed keywords

ACYLTRANSFERASE INHIBITOR; AZD 7687; DIACYLGLYCEROL ACYLTRANSFERASE 1; GASTROINTESTINAL HORMONE; GLUCAGON LIKE PEPTIDE 1; PARACETAMOL; PEPTIDE YY; PLACEBO; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ACETIC ACID DERIVATIVE; ANTIOBESITY AGENT; AZD7687; DGAT1 PROTEIN, HUMAN; DIACYLGLYCEROL ACYLTRANSFERASE; PYRAZINE DERIVATIVE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; ARTICLE; BLOOD PRESSURE; BODY TEMPERATURE; BREATHING RATE; CLINICAL ARTICLE; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; ENZYME INHIBITION; HEMATOLOGY; HORMONE RELEASE; HUMAN; LIPID DIET; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHASE 1 CLINICAL TRIAL; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMACH EMPTYING; TRIACYLGLYCEROL BLOOD LEVEL; URINALYSIS; VOMITING; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; INTESTINE ABSORPTION; MIDDLE AGED; TREATMENT OUTCOME; WEIGHT REDUCTION;

ACETATES; ADULT; ANTI-OBESITY AGENTS; DIABETES MELLITUS, TYPE 2; DIACYLGLYCEROL O-ACYLTRANSFERASE; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; GASTRIC EMPTYING; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INTESTINAL ABSORPTION; MALE; MIDDLE AGED; OBESITY; PEPTIDE YY; PYRAZINES; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84895079431     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12221     Document Type: Article

References (40)

1. Bradley D, Magkos F, Klein S. Effects of bariatric surgery on glucose homeostasis and type 2 diabetes. Gastroenterology 2012; 143: 897-912.
2. Pan X, Hussain MM. Gut triglyceride production. Biochim Biophys Acta 1821; 2012: 727-735.
3. Cao J, Zhou Y, Peng H et al. Targeting Acyl-CoA:diacylglycerol acyltransferase 1 (DGAT1) with small molecule inhibitors for the treatment of metabolic diseases. J Biol Chem 2011; 286: 41838-41851.
4. Smith SJ, Cases S, Jensen DR et al. Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking DGAT. Nat Genet 2000; 25: 87-90.
5. Streeper RS, Koliwad SK, Villanueva CJ, Farese RV Jr. Effects of DGAT1 deficiency on energy and glucose metabolism are independent of adiponectin. Am J Physiol Endocrinol Metab 2006; 291: E388-394.
6. Zhao G, Souers AJ, Voorbach M et al. Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor. J Med Chem 2008; 51: 380-383.
7. Okawa M, Fujii K, Ohbuchi K et al. Role of MGAT2 and DGAT1 in the release of gut peptides after triglyceride ingestion. Biochem Biophys Res Commun 2009; 390: 377-381.
8. Ables GP, Yang KJ, Vogel S et al. Intestinal DGAT1 deficiency reduces postprandial triglyceride and retinyl ester excursions by inhibiting chylomicron secretion and delaying gastric emptying. J Lipid Res 2012; 53: 2364-2379.
9. Liu L, Yu S, Khan RS et al. DGAT1 deficiency decreases PPAR expression and does not lead to lipotoxicity in cardiac and skeletal muscle. J Lipid Res 2011; 52: 732-744.
10. Birch AM, Buckett LK, Turnbull AV. DGAT1 inhibitors as anti-obesity and anti-diabetic agents. Curr Opin Drug Discov Devel 2010; 13: 489-496.
11. Chen HC, Farese RV Jr. Inhibition of triglyceride synthesis as a treatment strategy for obesity: lessons from DGAT1-deficient mice. Arterioscler Thromb Vasc Biol 2005; 25: 482-486.
12. Barlind JG, Bauer UA, Birch AM et al. Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). J Med Chem 2012; 55: 10610-10629.
13. Denison H, Nilsson C, Kujacic M et al. Proof of mechanism for the DGAT1 inhibitor AZD7687: results from a first-time-in-human single-dose study. Diabetes Obes Metab 2013; 15: 136-143.
14. Haas JT, Winter HS, Lim E et al. DGAT1 mutation is linked to a congenital diarrheal disorder. J Clin Invest 2012; 122: 4680-4684.
15. Karpe F. Effects of diet on postprandial lipaemia: a suggestion for methodological standardization. Nutr Metab Cardiovasc Dis 1997; 7: 44-55.
16. Willems M, Quartero AO, Numans ME. How useful is paracetamol absorption as a marker of gastric emptying? A systematic literature study. Dig Dis Sci 2001; 46: 2256-2262.
17. Buhman KK, Smith SJ, Stone SJ et al. DGAT1 is not essential for intestinal triacylglycerol absorption or chylomicron synthesis. J Biol Chem 2002; 277: 25474-25479.
18. Zhang XD, Yan JW, Yan GR et al. Pharmacological inhibition of diacylglycerol acyltransferase 1 reduces body weight gain, hyperlipidemia, and hepatic steatosis in db/db mice. Acta Pharmacol Sin 2010; 31: 1470-1477.
19. Carstensen M, Thomsen C, Hermansen K. Incremental area under response curve more accurately describes the triglyceride response to an oral fat load in both healthy and type 2 diabetic subjects. Metabolism 2003; 52: 1034-1037.
20. Spayd RW, Bruschi B, Burdick BA et al. Multilayer film elements for clinical analysis: applications to representative chemical determinations. Clin Chem 1978; 24: 1343-1350.
21. Kinoshita M, Kojima M, Matsushima T, Teramoto T. Determination of apolipoprotein B-48 in serum by a sandwich ELISA. Clin Chim Acta 2005; 351: 115-120.
22. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987; 2: 1300-1304.
23. Adrian TE, Ferri GL, Bacarese-Hamilton AJ, Fuessl HS, Polak JM, Bloom SR. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 1985; 89: 1070-1077.
24. le Roux CW, Batterham RL, Aylwin SJ et al. Attenuated peptide YY release in obese subjects is associated with reduced satiety. Endocrinology 2006; 147: 3-8.
25. Axelson M, Aly A, Sjövall J. Levels of 7 alpha-hydroxy-4-cholesten-3-one in plasma reflect rates of bile acid synthesis in man. FEBS Lett 1988; 239: 324-328.
26. Sauter G, Berr F, Beuers U, Fischer S, Paumgartner G. Serum concentrations of 7alpha-hydroxy-4-cholesten-3-one reflect bile acid synthesis in humans. Hepatology 1996; 24: 123-126.
27. Pattni SS, Brydon WG, Dew T, Walters JR. Fibroblast growth factor 19 and 7alpha-hydroxy-4-cholesten-3-one in the diagnosis of patients with possible bile acid diarrhea. Clin Transl Gastroenterol 2012; 3: e18.
28. Löfgren L, Ståhlman M, Forsberg GB, Saarinen S, Nilsson R, Hansson GI. The BUME method a novel automated chloroform-free 96-well total lipid extraction method for blood plasma. J Lipid Res 2012; 53: 1690-1700.
29. van der Hoorn J, Linden D, Lindahl U et al. Low dose of the liver X receptor agonist, AZ876, reduces atherosclerosis in APOE*3Leiden mice without affecting liver or plasma triglyceride levels. Br J Pharmacol 2011; 162: 1553-1563.
30. Homan R, Anderson MK. Rapid separation and quantitation of combined neutral and polar lipid classes by high-performance liquid chromatography and evaporative light-scattering mass detection. J Chromatogr B Biomed Sci Appl 1998; 708: 21-26.
31. Abraham BP, Kane S. Fecal markers: calprotectin and lactoferrin. Gastroenterol Clin North Am 2012; 41: 483-495.
32. Maciejewski BS, Laperle JL, Chen D et al. Pharmacological inhibition to examine the role of DGAT1 in dietary lipid absorption in rodents and humans. Am J Physiol Gastrointest Liver Physiol 2013; 304: G958-969.
33. Nauck MA, Kemmeries G, Holst JJ, Meier JJ. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes 2011; 60: 1561-1565.
34. Novartis. A 12-week multi-center, randomized, double-blind, placebo-controlled, parallel-group adaptive design study to evaluate the efficacy on blood glucose control and safety of five doses of LCQ908 (2, 5, 10, 15 and 20mg) or sitagliptin 100mg on a background therapy of metformin in obese patients with type 2 diabetes. 2010. Available from URL: http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=4313.
35. Little TJ, Horowitz M, Feinle-Bisset C. Modulation by high-fat diets of gastrointestinal function and hormones associated with the regulation of energy intake: implications for the pathophysiology of obesity. Am J Clin Nutr 2007; 86: 531-541.
36. Ammon HV, Phillips SF. Inhibition of ileal water absorption by intraluminal fatty acids. Influence of chain length, hydroxylation, and conjugation of fatty acids. J Clin Invest 1974; 53: 205-210.
37. Ramakrishna BS, Mathan M, Mathan VI. Alteration of colonic absorption by long-chain unsaturated fatty acids. Influence of hydroxylation and degree of unsaturation. Scand J Gastroenterol 1994; 29: 54-58.
38. Lapre JA, De Vries HT, Koeman JH, Van der Meer R. The antiproliferative effect of dietary calcium on colonic epithelium is mediated by luminal surfactants and dependent on the type of dietary fat. Cancer Res 1993; 53: 784-789.
39. Shores DR, Binion DG, Freeman BA, Baker PR. New insights into the role of fatty acids in the pathogenesis and resolution of inflammatory bowel disease. Inflamm Bowel Dis 2011; 17: 2192-2204.
40. Weylandt KH, Kang JX, Wiedenmann B, Baumgart DC. Lipoxins and resolvins in inflammatory bowel disease. Inflamm Bowel Dis 2007; 13: 797-799.